Following $40m Series A, Escient contacts Eurofins to advance drug discovery

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/uris)
(Image: Getty/uris)

Related tags: Eurofins, Drug discovery

Escient Pharmaceuticals has entered the market after closing a $40m Series A financing round – and has contacted Eurofins Discovery for integrated drug discovery services.

San Diego, CA-based Escient has turned to Eurofins' for its assay development and G-protein-coupled receptor (GPCR) drug discovery services to identify novel therapeutics targeting Mas-Related G-Protein Receptors (Mrgpr).

According to the company – which completed the Series A financing round in May 2018 – medicines for neuro-immuno-inflammatory and autoreactive diseases will initially be pursued.

As per the ‘ongoing’ collaboration, Eurofins will provide in vitro​ preclinical discovery services for Escient's programs. 

"The preclinical discovery support required for Escient's novel drug targets plays well to Eurofins' expertise and capabilities and this collaboration will greatly expedite our discovery path," ​said Marcus Boehm PhD, Escient’s chief scientific officer, in statement.

Christina Shasserre, senior vice president of Eurofins Discovery, said, "We have been offering services for all phases of drug discovery and can now assemble this offering into an integrated service with program management staffed from experts in drug discovery, termed DiscoveryOne.”

Related topics: Preclinical Research

Related news

Show more

Follow us

Products

View more

Webinars